BCMA-CD19 CAR-T

BCMA-CD19 CAR-T is an investigational compound chimeric antigen receptor (cCAR) T-cell therapy developed by Peking University People's Hospital for the treatment of multiple refractory autoimmune diseases. This dual-targeting biologic utilizes autologous T-cells engineered to express receptors for both CD19, which is expressed on B cells, and B-cell maturation antigen (BCMA), which is expressed on plasma cells and long-lived plasma cells. By targeting both populations, the therapy aims to achieve a more comprehensive depletion of the B-cell lineage, including the pathogenic autoantibody-producing plasma cells that often evade standard B-cell depleting therapies like rituximab. Clinical evaluation in Phase 2 trials has focused on patients with severe, refractory conditions such as systemic lupus erythematosus and systemic sclerosis, demonstrating the potential to induce clinical remission and eliminate circulating autoantibodies.

Other names

BCMA-CD19 targeted chimeric antigen receptor T-cell therapyBCMA-CD-19 targeted chimeric antigen receptor T-cell therapyBCMA-CD 19 targeted chimeric antigen receptor T-cell therapyBCMA-CD19-targeted CAR-T cellsBCMA-CD-19-targeted CAR-T cellsBCMA-CD 19-targeted CAR-T cellsBCMA/CD19 chimeric antigen receptor (CAR)-modified T cells